<DOC>
	<DOCNO>NCT02595138</DOCNO>
	<brief_summary>Triple-negative breast cancer special type breast cancer poor prgnosis limit choice . Chemotherapy choice adjuvant systemic treatment option . Previous study suggest zoledronic acid might anti-tumor effect eliminate number DTCs ( Disseminated Tumor Cell ) prove effective adjvant therapy postmenopausal woman whose breast cancer Homonal receptor positive receiving aromatase inhibitor . So might able improve survival triple negative breast cancer patient .</brief_summary>
	<brief_title>Zoledronic Acid Adjuvant Treatment Triple-negative Breast Cancer</brief_title>
	<detailed_description>Triple negative breast cancer patient high risk factor randomize receive either zoledronic acid observation completion standard chemotherapy/radiotherapy . Recurrence status follow Disease free survival compare . Overall survival secondary endpoint .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>•Adult woman ( ≥ 18 year age ) early stage breast cancer ( stage IIIII ) . Histological confirmation estrogen and/or progesteronereceptor negative ( ER ) , human epidermal growth factor receptor 2 negative ( HER2 ) breast cancer . ER/PR negative : nuclear reaction &lt; 1 % , HER2 negative : HER2 ; IHC 0,1+ FISH/CISH ( ) case IHC 2+ axillary lymph node positive high risk factor : LVI , T &gt; 5CM , Grade III Patients finish standard chemotherapy and/or radiotherapy ECOG performance status 0,1 Adequate bone marrow , hepatic , renal function Adequate bone marrow coagulation function show : Absolute neutrophil count ( ANC ) ≥ 1.5 109/L ; Platelets &gt; 100 x109/L ; Hemoglobin ( Hgb ) &gt; 9.0g/dLINR &lt; 2 Adequate liver function show : Serum aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2.5x ULN Total serum bilirubin &lt; 1.5 x ULN Adequate renal function show : Serum creatinine &lt; 1.5 x ULN Fasting serum cholesterol &lt; 300 mg/dL 7.75 mmol/L fast triglyceride &lt; 2.5 x ULN . In case one threshold exceed , patient include initiation statin therapy mention value achieve . Written inform consent •Another malignancy within 5 year prior enrollment exception adequately treat insitu carcinoma cervix , uteri , basal squamous cell carcinoma nonmelanomatous skin cancer . Any severe and/or uncontrolled medical condition , eg . currently active infection Pregnant lactating Patients unwilling unable comply protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>zoledronic acid</keyword>
	<keyword>triple-negative breast cancer</keyword>
	<keyword>adjuvant treatment</keyword>
</DOC>